NEOS Investment Management LLC Reduces Holdings in Amgen Inc. (NASDAQ:AMGN)

NEOS Investment Management LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 4.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 78,431 shares of the medical research company’s stock after selling 3,795 shares during the quarter. NEOS Investment Management LLC’s holdings in Amgen were worth $20,442,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in AMGN. UniSuper Management Pty Ltd boosted its position in shares of Amgen by 10.6% during the fourth quarter. UniSuper Management Pty Ltd now owns 88,798 shares of the medical research company’s stock valued at $23,144,000 after buying an additional 8,494 shares during the period. Sava Infond d.o.o. purchased a new position in Amgen during the 4th quarter valued at $808,000. Korea Investment CORP grew its position in Amgen by 2.4% in the 4th quarter. Korea Investment CORP now owns 372,291 shares of the medical research company’s stock valued at $97,034,000 after acquiring an additional 8,576 shares during the last quarter. Tyler Stone Wealth Management increased its stake in Amgen by 16.6% in the fourth quarter. Tyler Stone Wealth Management now owns 1,118 shares of the medical research company’s stock worth $291,000 after purchasing an additional 159 shares during the period. Finally, Aviso Wealth Management lifted its position in shares of Amgen by 12.0% during the fourth quarter. Aviso Wealth Management now owns 2,266 shares of the medical research company’s stock worth $590,000 after purchasing an additional 243 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft cut their price target on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. UBS Group reaffirmed a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Truist Financial lowered their price target on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a report on Wednesday, January 8th. Citigroup reissued a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $324.00 target price on shares of Amgen in a research report on Friday, January 24th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $314.04.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 in the last quarter. Corporate insiders own 0.69% of the company’s stock.

Amgen Stock Down 0.4 %

Shares of AMGN stock opened at $305.71 on Thursday. The stock’s 50-day simple moving average is $299.66 and its 200-day simple moving average is $298.46. The firm has a market capitalization of $164.23 billion, a PE ratio of 40.49, a P/E/G ratio of 2.63 and a beta of 0.53. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.11%. Amgen’s dividend payout ratio is presently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.